These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23023637)

  • 1. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
    Ureña Torres PA
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phosphate metabolism and nutritional therapy in predialysis patients].
    Hamada Y; Usami M
    Clin Calcium; 2012 Oct; 22(10):1577-82. PubMed ID: 23023639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphate management in chronic kidney disease.
    Bhan I
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate: a stealthier killer than previously thought?
    Gonzalez-Parra E; Tuñón J; Egido J; Ortiz A
    Cardiovasc Pathol; 2012; 21(5):372-81. PubMed ID: 22425627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
    Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
    Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
    Mukhin NA; Milovanov YS; Kozlovskaya LV; Dobrosmyslov IA; Milovanova LY
    Ter Arkh; 2016; 88(4):41-45. PubMed ID: 27070162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis.
    Kuhlmann MK
    Blood Purif; 2010; 29(2):137-44. PubMed ID: 20093819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
    Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
    J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and treatment of hyperphosphatemia in chronic kidney disease.
    Vervloet MG; van Ballegooijen AJ
    Kidney Int; 2018 May; 93(5):1060-1072. PubMed ID: 29580635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?
    Malindretos P
    Expert Opin Pharmacother; 2012 Nov; 13(16):2255-6. PubMed ID: 23046412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel iron-based phosphate binders in patients with chronic kidney disease.
    Shah HH; Hazzan AD; Fishbane S
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):330-5. PubMed ID: 26050119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.